Specifically, the observed reductions in adipose tissue weight, improvements in glucose homeostasis, and increases in energy expenditure in diet‐induced obese mice suggest that hADP promoter‐modified UCP1 overexpression plasmid therapy may have broad applicability in mitigating obesity phenotypes, including those with concomitant metabolic dysfunction. This evidence concerns the gene UCP1 and obesity disorder.